tiprankstipranks
Advertisement

HEAL - ETF AI Analysis

Compare

Top Page

HEAL

Global X HealthTech ETF (HEAL)

Rating:60Neutral
Price Target:
HEAL, the Global X HealthTech ETF, has a solid but not top-tier rating, reflecting a mix of strong innovators and some financially challenged names in the health technology space. High-quality holdings like GE Healthcare Technologies, Dexcom, and Resmed support the fund’s rating with strong financial performance, positive earnings commentary, and strategic growth initiatives, while weaker positions such as Oscar Health, Philips, and Masimo, which face profitability and revenue pressures, weigh on the overall score. The main risk for investors is that many holdings trade at rich valuations and several show bearish or weak technical trends, which can increase volatility in a sector-focused fund.
Positive Factors
Leading HealthTech Focus
The fund targets companies at the intersection of health care and technology, giving investors focused exposure to a growing niche of the market.
Strong Contribution From Top Holding Masimo
Masimo, the largest position in the ETF, has shown strong year-to-date performance, helping offset weakness in some other holdings.
Global Diversification Beyond the U.S.
While most assets are in U.S. companies, the fund also holds stocks from Europe, Asia, and Australia, adding some international diversification.
Negative Factors
Recent Weak Overall Performance
The ETF has delivered negative returns so far this year and over the last three months, indicating recent performance has been weak.
High Concentration In Health Care Sector
With the vast majority of assets in health care, the fund is heavily exposed to sector-specific risks such as regulatory changes and reimbursement pressures.
Several Key Holdings Are Lagging
Many of the larger positions, including Dexcom, GE Healthcare, TransMedics, Resmed, Alibaba Health, IQVIA, and Intuitive Surgical, have shown weak year-to-date performance, which can drag on the fund’s returns.

HEAL vs. SPDR S&P 500 ETF (SPY)

HEAL Summary

HEAL, the Global X HealthTech ETF, tracks the Global X HealthTech Index and focuses on companies using technology to improve healthcare. It holds businesses involved in telemedicine, digital health platforms, and remote monitoring tools. Well-known names in the fund include Philips and Intuitive Surgical. Someone might invest in HEAL if they believe digital healthcare will keep growing and want a simple way to spread their money across many health-tech companies instead of picking individual stocks. A key risk is that it is heavily focused on healthcare technology, so its price can swing a lot if this niche falls out of favor.
How much will it cost me?The Global X HealthTech ETF (HEAL) has an expense ratio of 0.5%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized sector like health technology, which requires more research and expertise.
What would affect this ETF?The Global X HealthTech ETF (EDOC) could benefit from increasing demand for telemedicine and digital health solutions as healthcare systems worldwide continue to embrace technology for efficiency and accessibility. However, potential risks include regulatory changes in healthcare technology or slower adoption rates in certain regions, which could impact the growth of companies in its portfolio. Additionally, economic downturns or rising interest rates might negatively affect the performance of smaller, innovative firms within the ETF.

HEAL Top 10 Holdings

HEAL is very much a bet on digital health, with most of its muscle in health care names rather than traditional tech. Oscar Health and Dexcom have been the fund’s main spark plugs lately, rising on optimism around digital insurance and glucose monitoring. Masimo is also quietly pulling its weight with steadier gains. On the flip side, GE Healthcare, Veeva, and Pro Medicus have been losing steam, acting as a drag. The portfolio is globally spread, but thematically it’s tightly wired to telemedicine and health-tech services.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Oscar Health5.87%$1.58M$8.56B39.76%
49
Neutral
Hims & Hers Health5.27%$1.42M$8.21B-20.10%
68
Neutral
Pro Medicus Limited4.89%$1.32MAU$18.05B-30.54%
69
Neutral
Dexcom4.81%$1.30M$27.96B-13.49%
79
Outperform
IQVIA Holdings4.33%$1.17M$28.00B8.14%
73
Outperform
Koninklijke Philips N.V.4.17%$1.12M€22.84B21.58%
56
Neutral
GE Healthcare Technologies Inc4.11%$1.11M$28.02B-14.78%
78
Outperform
Alignment Healthcare3.86%$1.04M$4.52B56.59%
60
Neutral
Tempus AI, Inc. Class A3.77%$1.01M$9.13B-27.11%
52
Neutral
Resmed3.75%$1.01M$27.36B-25.96%
76
Outperform

HEAL Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
25.34
Positive
100DMA
25.43
Positive
200DMA
28.28
Negative
Market Momentum
MACD
0.33
Negative
RSI
62.69
Neutral
STOCH
49.11
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HEAL, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 25.60, equal to the 50-day MA of 25.34, and equal to the 200-day MA of 28.28, indicating a neutral trend. The MACD of 0.33 indicates Negative momentum. The RSI at 62.69 is Neutral, neither overbought nor oversold. The STOCH value of 49.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HEAL.

HEAL Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$27.73M0.50%
60
Neutral
$42.03M0.50%
58
Neutral
$39.74M0.80%
63
Neutral
$21.33M0.44%
66
Neutral
$17.80M0.85%
65
Neutral
$10.23M0.55%
64
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HEAL
Global X HealthTech ETF
26.68
-4.90
-15.52%
FMED
Fidelity Disruptive Medicine ETF
MEDI
Harbor Health Care ETF
TMED
T. Rowe Price Health Care ETF
MEDX
Horizon Kinetics Medical ETF
BMED
Future Health ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement